Therefore, to better evaluate the clinical efficacy of ICIs for ESCC, we included not only PD-L1 unselected ESCC patients but also those with PD-L1 expression ≥10% and PD-L1 expression ≥1%. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.